NYSE:NVRONevro Stock Price, Forecast & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 3.9% and is now trading at $114.09. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nevro.

Nevro is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nevro.

Nevro Corp (NYSE:NVRO) released its earnings results on Tuesday, May, 5th. The medical equipment provider reported ($0.78) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.99) by $0.21. The medical equipment provider had revenue of $87.47 million for the quarter, compared to the consensus estimate of $86.70 million. Nevro had a negative net margin of 21.36% and a negative return on equity of 40.67%. Nevro's revenue was up 6.5% on a year-over-year basis. During the same period last year, the company posted ($1.45) earnings per share. View Nevro's earnings history.

12 brokerages have issued twelve-month target prices for Nevro's shares. Their forecasts range from $65.00 to $158.00. On average, they anticipate Nevro's share price to reach $120.83 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price. View analysts' price targets for Nevro.

Headlines about NVRO stock have been trending very negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nevro earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Nevro.

Some companies that are related to Nevro include Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Tandem Diabetes Care (TNDM), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Irhythm Technologies (IRTC), NuVasive (NUVA), Inari Medical (NARI) and Merit Medical Systems (MMSI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Adobe (ADBE), AbbVie (ABBV), Trade Desk (TTD), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP) and Vertex Pharmaceuticals (VRTX).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.04%), Polianta Ltd (0.03%) and FNY Investment Advisers LLC (0.02%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle and Shawn Mccormick. View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, and Shawn Mccormick. View insider buying and selling activity for Nevro.

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Polianta Ltd, and FNY Investment Advisers LLC. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle. View insider buying and selling activity for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $114.09.

Nevro has a market capitalization of $3.88 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]